This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health Corporation (CVS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. CNC, CVS, ODP, STNE and PSFE are some such stocks.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Invest in This Dream 5-Stock Diversified Portfolio for Gains in 2H
by Nalak Das
CVNA, JBL, HWM, NRG and CVS surged over 50% in 1H 2025. This 5-stock portfolio still shows short-term upside potential.
CVS vs. Amazon: Healthcare Battle Continues- Which Stock to Buy Now?
by Urmimala Biswas
CVS surges with a 56% YTD return and an integrated care model, as AMZN bets on tech and logistics to reshape healthcare.
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
CVS vs. DHR: Which Stock Is the Better Value Option?
by Zacks Equity Research
CVS vs. DHR: Which Stock Is the Better Value Option?
Are Medical Stocks Lagging CVS Health (CVS) This Year?
by Zacks Equity Research
Here is how CVS Health (CVS) and Agenus (AGEN) have performed compared to their sector so far this year.
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
by Zacks Equity Research
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
by Zacks Equity Research
TMDX continues to witness growth on the back of its strength in OCS technology and the National OCS Program.
CVS Health (CVS) Laps the Stock Market: Here's Why
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $67.58, moving +1.15% from the previous trading session.
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL continues to witness growth on the back of its strong product portfolio.
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
BBNX Stock May Gain From Abbott Deal to Advance iLet Integration
by Zacks Equity Research
Beta Bionics collaborates with Abbott to integrate its iLet system with a dual sensor, aiming to simplify and enhance diabetes care.
Why CVS Health (CVS) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
by Zacks Equity Research
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
Investors Heavily Search CVS Health Corporation (CVS): Here is What You Need to Know
by Zacks Equity Research
CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GE HealthCare Stock Slips Despite the Launch of bkActiv S Series
by Zacks Equity Research
GEHC expands its bkPortfolio with the AI-powered bkActiv S Series to advance ultrasound-guided procedures.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
Two Healthcare Heavyweights, One Winner: UnitedHealth or CVS Health?
by Kaibalya Pravo Dey
CVS gains steam as rising margins, strong Medicare results, and cost cuts set it apart from UNH.
Exploring CVS' Health Services Segment: A Key Growth Engine for 2025?
by Moumi Mondal
CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.
CVS Surges on Regulatory Relief, Medicare Advantage Push: Time to Buy?
by Urmimala Biswas
CVS surges 53.7% YTD as regulatory relief, strong execution and Medicare Advantage momentum fuel investor confidence.
VEEV Stock May Gain on the Launch of China Campaign Manager for Pharma
by Zacks Equity Research
Veeva Systems launches China Campaign Manager to boost pharma engagement with localized, compliant CRM-driven solutions.
5 Low Price-to-Book Value Stocks That You Can Buy in June
by Kinjel Shah
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.